Drug Research
Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
Arena Pharmaceuticals, Inc. and Beacon Discovery announced that they entered into a strategic multi-year partnership (Project Cabrillo) aimed at building novel medicines across a range of G protein-coupled receptor (GPCR) targets.
Under the terms of the deal, Beacon will be...
IT & Data Management
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*. Through the agreement, the Lung...
Drug Research
Vaccitech partners with CRUK on NSCLC immunotherapeutic vaccine
Vaccitech has signed a partnership with Cancer Research UK (CRUK) to clinically advance VTP-600, the former’s immunotherapy vaccine candidate, for patients with non-small cell lung cancer (NSCLC).
According to the terms of the agreement, CRUK’s Centre for Drug Development will...
Press Releases
Clinerion and Pangaea partner to improve cancer patient lives
Clinerion, provider of the Patient Network Explorer platform which harnesses patient data from a global hospital network, and Pangaea, a machine learning company, partner to improve faster identification of patient cohorts based on phenotypes from electronic health record (EHR)...
Press Releases
CPhI & P-MEC India 2019 growth mirrors the market’s positive outlook heading into 2020
CPhI & P-MEC India 2019 – organised by Informa Markets – recently closed its doors to over 45,000 visitors and 1,600+ exhibitors from 44 countries, making it the largest pharmaceutical trade show in South Asia. Mirroring the event’s success,...
Press Releases
XTANDI approved by U.S. FDA for the treatment of metastatic castration-sensitive prostate cancer
Pfizer Inc and Astellas Pharma Inc announced that the U.S. FDA has approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). In 2019, it is estimated that...
Press Releases
Novartis announces partnership with Amazon to digitally transform operations
Novartis will work with Amazon Web Services (AWS) to increase efficiencies across its manufacturing, supply chain and delivery operations. The company will use AWS’ portfolio of cloud services to create custom solutions which use artificial intelligence and machine learning...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read